ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 1147 • 2018 ACR/ARHP Annual Meeting

    Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany

    Klaus Krüger1, Sven Remstedt2, Astrid Thiele3 and Ines Klaudius4, 1Medical Centre of Rheumatology, Munich, Germany, 2Rheuma Praxis Berlin, Berlin, Germany, 3Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 4MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany.…
  • Abstract Number: 1654 • 2018 ACR/ARHP Annual Meeting

    Improvement of Cytological Grade and Tear Production in Ankylosing Spondylitis Patients Under Anti-TNF Therapy: A Long-Term Follow-up

    Fany Usuba1, Carla GS Saad2, Priscila Novaes1, Ruth Santo1, Julio CB Moraes2, Eloisa Bonfa3 and Milton Alves4, 1Ophtalmology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4Ophtalmolgy Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Clinical expression and pathophysiology of dry eye disease (DED) have recently changed and pro-inflammatory cytokines, such as TNF-α, may play a role in the…
  • Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting

    Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany

    Klaus Krüger1, Gerd R. Burmester2, Siegfried Wassenberg3, Valeria Biermann4 and Matthias H. Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 3Rheumazentrum Ratingen, Ratingen, Germany, 4Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, 5Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
  • Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting

    Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data

    Mikhail Protopopov1, Fabian Proft1, Alexandre Sepriano2,3, Robert B.M. Landewé4,5, Désirée van der Heijde2, Joachim Sieper1, Martin Rudwaleit6,7 and Denis Poddubnyy1,8, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, 4Zuyderland Medical Center, Heerlen, Netherlands, 5Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, 6Charité Universitätsmeidzin Berlin, Berlin, Germany, 7Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, 8German Rheumatism Research Centre, Berlin, Germany

    Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
  • Abstract Number: 1189 • 2018 ACR/ARHP Annual Meeting

    Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective

    Dam Kim1, Hyojin Kim2, Seongha Cho2 and Min-Chan Park1, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of (South), 2Patient Access Team, Novartis Korea, Seoul, Korea, Republic of (South)

    Secukinumab versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean PerspectiveDam Kim1, Hyojin Kim2, SeongHa Cho2, Min-Chan Park11Division of…
  • Abstract Number: 1830 • 2018 ACR/ARHP Annual Meeting

    Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis

    Yukiko Maeda1, Jozsef Karman2 and Ellen M. Gravallese3, 1Medicine, University of Massachusetts Medical School, Worcester, MA, 2Abbvie Bioresearch Center, Worcester, MA, 3Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Spondyloarthritis (SpA) is common, with a prevalence of ~1% in the United States. Patients with SpA suffer from pain and disability due to inflammation…
  • Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting

    The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action

    Santiago Rodrigues Manica1,2, Joana Leite Silva3, Ana Rita Machado4, Constança Coelho5, Joana Duarte6, Elsa Vieira-Sousa7, José Tavares Costa8 and Fernando Pimentel-Santos1,2, 1CEDOC, NOVA Medical School, Lisbon, Portugal, 2Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, 3Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, 4Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, 5Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, 6Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, 7Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, 8Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal

    Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
  • Abstract Number: 670 • 2018 ACR/ARHP Annual Meeting

    Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison

    Jürgen Braun1, Hildrun Haibel2, Manouk de Hooge3, Robert B.M. Landewé4, Martin Rudwaleit5, Todd Fox6, Aimee Readie7, Hanno Richards6, Brian Porter8, Ruvie Martin7, Denis Poddubnyy9, Joachim Sieper10 and Désirée van der Heijde11, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Charité Universitätmedizin Berlin, Berlin, Germany, 3Leiden University Medical Center, Leiden, Netherlands, 4Maastricht Univ Medical Center, Maastricht, Netherlands, 5Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 9Charité Universitätsmedizin Berlin, Berlin, Germany, 10Charité Universitätsmeidzin Berlin, Berlin, Germany, 11Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes IL-17A, improved signs and symptoms of ankylosing spondylitis (AS) in patients (pts) in the MEASURE 1…
  • Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting

    High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment

    Konstantinos Thomas1, Anastasia Makris1, Christina Tsalapaki1, Argyro Lazarini1, Kalliopi Klavdianou1, Katerina Antonatou1, Christos Koutsianas1, Chrisoula Hatzara1, Emilia Hadziyannis1 and Dimitrios Vassilopoulos2, 1Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 2Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
  • Abstract Number: 1831 • 2018 ACR/ARHP Annual Meeting

    Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity

    Zaied Ahmed Bhuyan1, M. Arifur Rahman2, Muralidhara Maradana1, Ahmed Mehdi3, Giuliana Guggino4, Paul Leo5, Linda Rehaume1, Matthew Brown5, Francesco Ciccia4 and Ranjeny Thomas1, 1The University of Queensland Diamantina Institute, Brisbane, Australia, 2Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, 3Diamantina Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, 4Rheumatology Unit, University of Palermo, Palermo, Italy, 5Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia

    Background/Purpose: Loss of function RUNX3 variants are associated with ankylosing spondylitis (AS) risk but the mechanism is unknown. Disturbances in immune regulation, intestinal microbial dysbiosis…
  • Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting

    Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)

    Arvind Chopra1, Nagnath Khadke2, Manjit Saluja3, Toktam Kainifard4 and Anuradha Venugopalan5, 1Center for Rheumatic Diseases, Pune, India, 2Rheumatolgy, Consultant, Pune, India, 3Rheumatology, Research Co-ordinator, Pune, India, 4Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), 5Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India

    Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic  regimen (Chopra…
  • Abstract Number: 672 • 2018 ACR/ARHP Annual Meeting

    Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis

    Seong-Kyu Kim1 and Jung-Yoon Choe2, 1Rheumatology, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), 2Department of Internal Medicine, Catholic university of Daegu School of Medicine, Daegu, Korea, Republic of (South)

    Background/Purpose: NLRP3 inflammasome is a molecular platform triggering activation of inflammatory cytokines including interleukin-1b (IL-1b). This study aimed to assess the expression of NLRP3 inflammasome…
  • Abstract Number: 1384 • 2018 ACR/ARHP Annual Meeting

    Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States

    W. Benjamin Nowell1, Regan Reynolds1, Kelly Gavigan1, Shilpa Venkatachalam1, Marie de la Cruz2, Emuella Flood2, Ethan Schwartz2, Beverly Romero2, Yujin Park3 and Alexis Ogdie4, 1Global Healthy Living Foundation, Upper Nyack, NY, 2ICON, Gaithersburg, MD, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily the sacroiliac joints and spine and can cause irreversible damage. Measuring disease…
  • Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting

    Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

    Désirée van der Heijde1, James Cheng-Chung Wei2, Maxime Dougados3, Philip J. Mease4, Atul A. Deodhar5, Walter P. Maksymowych6, Filip van Den Bosch7, Joachim Sieper8, Tetsuya Tomita9, Robert B.M. Landewé10, Lotus Mallbris11, Fangyi Zhao11, David Adams11, Beth Pangallo11 and Hilde Carlier11, 1Leiden University Medical Centre, Leiden, Netherlands, 2Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, 3Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, 4Swedish Medical Center and University of Washington, Seattle, WA, 5Oregon Health & Science U, Portland, OR, 6University of Alberta, Edmonton, AB, Canada, 7Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 8Charité University Hospital, Berlin, Germany, 9Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, 10Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 11Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
  • Abstract Number: 673 • 2018 ACR/ARHP Annual Meeting

    Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time

    John D. Reveille1, MinJae Lee2, Laura A. Diekman3, Michael Ward4, Lianne S. Gensler5, Amirali Tahanan2, Mohammad H. Rahbar6 and Michael Weisman7, 1McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 2Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, 3Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, 4National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, 5University of California San Francisco, San Francisco, CA, 6Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, 7Harbor UCLA Medical Center, Los Angeles, CA

    Background/Purpose: We examined first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) patients with chronic inflammatory back pain (CIBP), non-inflammatory CBP (NICBP) and no…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology